Prognostic role of the stromal tumor-infiltrating lymphocytes (TILs) in women with early ER+/HER2+breast cancer (BC) in whom adjuvant chemotherapy (ChT) was omitted.

被引：0
|
作者：
Horvat, Valentina Jeric
Manevski, Damjan
Gazic, Barbara
Drev, Primoz
Matos, Erika
Ribnikar, Domen
Seruga, Bostjan
机构：
[1] Inst Oncol Ljubljana, Div Med Oncol, Ljubljana, Slovenia
[2] Univ Ljubljana, Inst Biostat & Med Informat, Fac Med, Ljubljana, Slovenia
[3] Inst Oncol Ljubljana, Dept Pathol, Ljubljana, Slovenia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12526
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41.
    Schlam, Ilana
    Tang, Gong
    Harris, Brent T.
    Rastogi, Priya
    Wolmark, Norman
    Salgado, Roberto
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Effect of tumor infiltrating lymphocytes (TILs) and stromal CD68 on trastuzumab (T) benefit in early stage HER2 positive breast cancer (BC).
    Raphael, Jacques
    Gong, Inna Y.
    Nofech-Mozes, Sharon
    Bartlett, John M. S.
    Nafisi, Houman
    Verma, Sunil
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] Prognostic Implication of Tumor-Infiltrating Lymphocytes in Patients With HER2-Positive Breast Cancer
    Yoshida, E. J.
    Li, Q.
    Chung, A.
    Knudsen, B.
    Burnison, M.
    Mirhadi, A. J.
    Zumsteg, Z. S.
    Giuliano, A. E.
    Amersi, F. F.
    Shiao, S. L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S44 - S45
  • [24] Prognostic value of tumor-infiltrating lymphocytes in small HER2-positive breast cancer
    Criscitiello, C.
    Bagnardi, V.
    Pruneri, G.
    Vingiani, A.
    Esposito, A.
    Rotmensz, N.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [25] Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
    Yang, Xia
    Rao, Jia
    Yang, Wentao
    Shui, Ruohong
    TARGETED ONCOLOGY, 2018, 13 (06) : 757 - 767
  • [26] Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+BC)
    Loi, S.
    Michiels, S.
    Salgado, R.
    Sirtaine, N.
    Jose, V.
    Fumagalli, D.
    Brown, D. N.
    Kellokumpu-Lehtinen, P-L
    Bono, P.
    Kataja, V.
    Desmedt, C.
    Piccart-Gebhart, M. J.
    Loibl, S.
    Untch, M.
    Denkert, C.
    Smyth, M. J.
    Joensuu, H.
    Sotiriou, C.
    CANCER RESEARCH, 2013, 73
  • [27] Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy
    Xia Yang
    Jia Rao
    Wentao Yang
    Ruohong Shui
    Targeted Oncology, 2018, 13 : 757 - 767
  • [28] A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+Breast Cancer
    Miglietta, Federica
    Ragazzi, Moira
    Fernandes, Bethania
    Griguolo, Gaia
    Massa, Davide
    Girardi, Fabio
    Bottosso, Michele
    Bisagni, Alessandra
    Zarrilli, Giovanni
    Porra, Francesca
    Iannaccone, Daniela
    Dore, Leocadia
    Gaudio, Mariangela
    Santandrea, Giacomo
    Fassan, Matteo
    Lo Mele, Marcello
    De Sanctis, Rita
    Zambelli, Alberto
    Bisagni, Giancarlo
    Guarneri, Valentina
    Dieci, Maria Vittoria
    CLINICAL CANCER RESEARCH, 2023, 29 (17) : 3429 - 3437
  • [29] Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
    Kurozumi, Sasagu
    Inoue, Kenichi
    Matsumoto, Hiroshi
    Fujii, Takaaki
    Horiguchi, Jun
    Oyama, Tetsunari
    Kurosumi, Masafumi
    Shirabe, Ken
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [30] Prognostic utility of tumor-infiltrating lymphocytes in residual tumor after neoadjuvant chemotherapy with trastuzumab for HER2-positive breast cancer
    Sasagu Kurozumi
    Kenichi Inoue
    Hiroshi Matsumoto
    Takaaki Fujii
    Jun Horiguchi
    Tetsunari Oyama
    Masafumi Kurosumi
    Ken Shirabe
    Scientific Reports, 9
12345